Fast-tracking the future
of molecular glues

Coltac is committed to discovering the next generation of molecular glues by harnessing the power of our bacteria-based, synthetic positive selection screening system.

The challenges

Signal to Noise Ratio

Many discovery platforms suffer from low signal to noise ratio, mainly due to pathway redundancy, deubiquitinase activity (DUB) and tight regulation.

Model Complexity

Biological complexity and variability in cellular responses make data interpretation challenging, requiring advanced techniques to distinguish meaningful outcomes from noise.

Narrow Target Space

Most programs today rely primarily on the same E3 ligases, facing limitations in discovery options and chemical space, resulting in false positives and costly, lengthy processes.

BOND+, a revolutionary
discovery platform

01

02

03

In-silico HTS

Implementing advanced structural expertise embedded in rationale high-throughput screening (“HTS”)

Bacterial-based discovery platform

We use split antibiotic resistance protein fragments fused to Ub and targets, co-expressed in bacteria with a synthetic ubiquitylation apparatus, to identify molecular glues that enhance target ubiquitylation

Hit-to-lead

Accelerated hit-to-lead optimization by iterating cycles of lead optimization leveraging bacterial growth as a positive signal screening platform

Coltac’s discovery processes seamlessly integrate advanced in-silico screening, powered by deep structural expertise, with a patented bacterial-based HTS platform that generates positive signals for superior signal-to-noise outcomes.

Together, these technologies form BOND+, an elegant, efficient, and highly selective discovery platform.

Coltac’s discovery processes seamlessly integrate advanced in-silico screening, powered by deep structural expertise, with a patented bacterial-based HTS platform that generates positive signals for superior signal-to-noise outcomes.

Together, these technologies form BOND+, an elegant, efficient, and highly selective discovery platform.

Our advantages

Robust

No interference from deubiquitinates, proteasome / lysosomes, or redundant ligases, ensuring accurate and reliable screening results.

High Signal to Noise Ratio

Very low false positive hit rate, as molecular glues are discovered based on their ability to enhance binding and ubiquitylation of target proteins.

Versatile

Exceptional sensitivity in investigating protein pairs (PPI) across indications, using bacterial growth as a positive signal for fast, cost-efficient, and reproducible interactions.

Breaking new ground

Coltac is already working with unique ligases on high-value targets. Our rapid transition from virtual screening to high-throughput bacterial validation accelerates the development of next-generation drugs for oncology and other therapeutic areas.

We enhance traditional methods with highly advanced and efficient screening capabilities, to discover the next generation of molecular glues.

We enhance traditional methods with highly advanced and efficient screening capabilities, to discover the next generation of molecular glues.

We enhance traditional methods with highly advanced and efficient screening capabilities, to discover the next generation of molecular glues.

The people
of Coltac

Our team of visionary scientists and innovators drives Coltac’s mission to advance molecular glue discovery and create transformative therapies.

Sarit Steinberg, LLM
Board member
Yaron Daniely, PhD, MBA
Board member
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
Tali Aloya, PhD
Board member
Sarit Steinberg, LLM
Board member
Yaron Daniely, PhD, MBA
Board member
Valeria Arkadash, PhD
Scientist
Hana Boocholez-Vardi, PhD
Scientist
Tali Aloya, PhD
Board member
Sarit Steinberg, LLM
Board member
Yaron Daniely, PhD, MBA
Board member
Valeria Arkadash, PhD
Scientist
Hana Boocholez-Vardi, PhD
Scientist
Yaron Sfadyah, LL.B, B.A
CEO
Orli Even-Or, PhD
Director of R&D
Michael Mullokandov, PhD
Senior Scientist
Hana Boocholez-Vardi, PhD
Scientist
Valeria Arkadash, PhD
Senior scientist
Gali Prag, PhD
Co-founder & board member
Yaron Daniely, PhD, MBA
Board member
Sarit Steinberg, LLM
Board member
Tali Aloya, PhD
Board member

Fostering science through strategic partnerships and venture support

amoon vcs
israel biotech fund
ramot tel aviv university